Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Boehringer Ingelheim Enrolls First Patient to Evaluate nintedanib for Pediatric Fibrosing ILD

americanpharmaceuticalreviewAugust 17, 2020

Tag: Boehringer Ingelheim , ILD , nintedanib , trial

PharmaSources Customer Service